AAP
EDIT icon

Arax Advisory Partners’s Editas Medicine EDIT Stock Holding History

Arax Advisory Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.9K Buy
7,365
+7,194
+4,207% +$21K ﹤0.01% 3834
2026
Q1 		$361 Sell
171
-4
-2% -$8 ﹤0.01% 3464
2025
Q4 		$359 Sell
175
-6,354
-97% -$18.3K ﹤0.01% 3651
2025
Q3 		$22.7K Buy
6,529
+6,379
+4,253% +$17.8K ﹤0.01% 2207
2025
Q2 		$330 Hold
150
– – ﹤0.01% 2961
2025
Q1 		$174 Buy
+150
New +$221 ﹤0.01% 2605
2020
Q3 		– Sell
-160
Closed -$5K – 694
2020
Q2 		$5K Hold
160
– – ﹤0.01% 592
2020
Q1 		$3K Buy
+160
New +$4.04K ﹤0.01% 602

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Arax Advisory Partners's EDIT Position: Q2 2026 in Review

Arax Advisory Partners increased its Editas Medicine (EDIT) stake by 4,207% in Q2 2026, buying an estimated $21K and bringing the position to 7,365 shares worth $23.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3834.

Arax Advisory Partners first reported a position in EDIT in Q1 2020 and has held it in 8 quarters since. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Arax Advisory Partners held 7,365 shares of Editas Medicine worth $23.9K as of Q2 2026.
  • Arax Advisory Partners bought 7,194 Editas Medicine shares in Q2 2026, an estimated $21K.
  • Editas Medicine made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3834 holding.
  • Arax Advisory Partners first reported a position in Editas Medicine in Q1 2020 and has held it in 8 quarters since.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.